PURPOSE: The purpose of this study was to examine patterns of circadian activity rhythms and their relationship with fatigue, anxiety/depression, and demographic/medical variables in women receiving breast cancer adjuvant therapy treatments (Tx) at three times within a randomized clinical trial (RCT) designed to improve sleep and modify fatigue. METHODS: A RCT enrolled 219 women with stageI-IIIA breast cancer who were randomized 2 days prior to starting chemotherapy to a behavioral therapy sleep intervention or healthy eating control group. All cases with available data (n = 190) were included in a descriptive, correlational, repeated measures analysis. Activity data were collected continuously by wrist actigraphy for 7 days at three times: the start (Tx 1), continuation (Tx 3), and recovery (30 days after last Tx) of chemotherapy. Circadian activity rhythm parameters were generated using Action4 software (Ambulatory Monitoring, Inc.). Measures collected simultaneously included Piper Fatigue Scale, Hospital Anxiety and Depression Scale, and demographic/medical variables. RESULTS:Circadian activity rhythm parameters at three times in both groups were disrupted compared to healthy adults, but similar to values of cancer patients. Significant changes in mesor, amplitude, peak activity, and 24 h autocorrelation values were found over time in both groups. The intervention group's amplitude and circadian quotient values were significantly more robust. More robust activity rhythms were associated with lower fatigue, depressive symptoms, body mass index, and higher performance status in both groups. CONCLUSIONS: Disrupted patterns of circadian activity rhythms were prevalent and associated with distressing fatigue and depressive symptoms during chemotherapy and at recovery. The intervention resulted in more robust rhythms.
RCT Entities:
PURPOSE: The purpose of this study was to examine patterns of circadian activity rhythms and their relationship with fatigue, anxiety/depression, and demographic/medical variables in women receiving breast cancer adjuvant therapy treatments (Tx) at three times within a randomized clinical trial (RCT) designed to improve sleep and modify fatigue. METHODS: A RCT enrolled 219 women with stage I-IIIA breast cancer who were randomized 2 days prior to starting chemotherapy to a behavioral therapy sleep intervention or healthy eating control group. All cases with available data (n = 190) were included in a descriptive, correlational, repeated measures analysis. Activity data were collected continuously by wrist actigraphy for 7 days at three times: the start (Tx 1), continuation (Tx 3), and recovery (30 days after last Tx) of chemotherapy. Circadian activity rhythm parameters were generated using Action4 software (Ambulatory Monitoring, Inc.). Measures collected simultaneously included Piper Fatigue Scale, Hospital Anxiety and Depression Scale, and demographic/medical variables. RESULTS: Circadian activity rhythm parameters at three times in both groups were disrupted compared to healthy adults, but similar to values of cancerpatients. Significant changes in mesor, amplitude, peak activity, and 24 h autocorrelation values were found over time in both groups. The intervention group's amplitude and circadian quotient values were significantly more robust. More robust activity rhythms were associated with lower fatigue, depressive symptoms, body mass index, and higher performance status in both groups. CONCLUSIONS: Disrupted patterns of circadian activity rhythms were prevalent and associated with distressing fatigue and depressive symptoms during chemotherapy and at recovery. The intervention resulted in more robust rhythms.
Authors: Luciane de Souza; Ana Amélia Benedito-Silva; Maria Laura Nogueira Pires; Dalva Poyares; Sergio Tufik; Helena Maria Calil Journal: Sleep Date: 2003-02-01 Impact factor: 5.849
Authors: Michael Littner; Clete A Kushida; W McDowell Anderson; Dennis Bailey; Richard B Berry; David G Davila; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Daniel Loube; Merrill Wise; Stephen F Johnson Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Sandra A Mitchell; Susan L Beck; Linda Edwards Hood; Karen Moore; Ellen R Tanner Journal: Clin J Oncol Nurs Date: 2007-02 Impact factor: 1.027
Authors: Meredith E Rumble; Stephen L Rose; Kaitlin Hanley White; A Holliston Moore; Philip Gehrman; Ruth M Benca; Erin S Costanzo Journal: Gynecol Oncol Date: 2015-04-21 Impact factor: 5.482
Authors: Bradley E Aouizerat; Anand Dhruva; Steven M Paul; Bruce A Cooper; Kord M Kober; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-05-29 Impact factor: 3.612
Authors: Heather S L Jim; Paul B Jacobsen; Kristin M Phillips; Robert M Wenham; William Roberts; Brent J Small Journal: Health Psychol Date: 2013-02-25 Impact factor: 4.267
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: Kathryn E Flynn; Rebecca A Shelby; Sandra A Mitchell; Maria R Fawzy; N Chantelle Hardy; Aatif M Husain; Francis J Keefe; Andrew D Krystal; Laura S Porter; Bryce B Reeve; Kevin P Weinfurt Journal: Psychooncology Date: 2010-10 Impact factor: 3.894
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908